John A. Stalfort III
John A. Stalfort III's purchase track record
John A. Stalfort III has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2023 | TSHA | $700K | -13.0% | -24.3% | +13.5% |
| 7/5/2022 | VRCA | $500K | +18.0% | +15.2% | -0.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.
Transaction History
| ABOS | ▲ Buy | Grant | 35,500 | $0 | 6/3/2026 | View on chart |
| TSHA | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 | View on chart |
| ABOS | ▲ Buy | Grant | 12,800 | $0 | 6/4/2025 | View on chart |
| TSHA | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 | View on chart |
| VRCA | ▼ Sell | Gift | 50,000 | $0 | 11/26/2024 | View on chart |
| VRCA | ▲ Buy | Open Market | 1,123,595 | — | 11/22/2024 | View on chart |
| TSHA | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 | View on chart |
| TSHA | ▲ Buy | Open Market | 388,889 | $350K | 8/16/2023 | View on chart |
| TSHA | ▲ Buy | Open Market | 388,889 | $350K | 8/16/2023 | View on chart |
| TSHA | ▼ Sell | Gift | 50,000 | $0 | 8/16/2023 | View on chart |
| VRCA | ▲ Buy | Open Market | 238,095 | $500K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.